替比夫定治疗慢性乙型肝炎的临床研究

目的探讨替比夫定治疗慢性乙型肝炎的疗效。方法将160例患者随机分为治疗组和对照组,各80例。治疗组给予替比夫定治疗,对照组给予拉米夫定治疗,疗程为24周。结果治疗组患者第4周、12周和24周各时间段HBVDNA低于检测下限的比率明显高于对照组(P0.01)。两组患者治疗第4周HBeAg低于检测下限的比率均为0,治疗组患者第12周、24周HBeAg低于检测下限的比率均明显高于对照组(P0.05)。治疗组和对照组患者第4周ALT复常率分别为5.0%和2.5%,无统计学意义;治疗12周、24周后治疗组患者ALT复常率均明显高于对照组(P0.05)。治疗24周后治疗组完全应答率明显高于对照组,无应答率明显低于对照组(P0.05)。两组不良反应发生率分别为10%和15%,无统计学差异。结论替比夫定能有效抑制HBV复制,提高HBVDNA、HBeAg低于检测下限的比率和ALT复常率,临床使用安全,耐受性好。

Clinical study on telbivudine treatment on chronic hepatitis B

Objective To evaluate the efficacy of telbivudine treatment on patients with chronic hepatitis B. Methods Total of 160 patients were randomly divided into treatment group （80 cases） and control group （80 cases）, who were given telbivudine and lamivudine for 24 weeks, respectively. Results HBV DNA undetectable rate of patients treated with telbivudine for 4, 12 and 24 weeks were significantly higher than that in control group （P 〈 0. 01 ）. HBeAg undetectable rate and ALT normalization rate of treatment group after 12 and 24 weeks were significantly higher than that in control group （ P 〈 0.. 05）. After 24 weeks of treatment, complete response rate of treatment group was significantly higher than that in control group （P 〈 0.05 ） , non-response rate of treatment group was significantly lower than that in control group （ P 〈 0.05 ）. The adverse reaction rate of two groups were 10% and 15% , which were not statistically significant （P 〈 0.05 ）. Conclusions Telbivudine can effectively inhibit replication of hepatitis B virus and improve undeteetable rate of HBV DNA and HBeAg, also promote normalization rate of ALT. In addition, telbivudine treatment is safe and well tolerant.